The Pharma Data

FEBRUARY 22, 2021

By 2030, Bayer aspires to reach gender parity on each individual management level. Moreover, Bayer strives to increase the proportion of people with disabilities in the workforce to more than 5 percent by 2030. In Germany, for example, it is currently 4.5

Compliance 40

Compliance Regulations 40

The Pharma Data

MAY 31, 2022

The initiative is supported by a multidisciplinary Steering Committee of patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders from around the world, with a mission to increase global adoption of biosimilar medicines by at least 30% in 30+ countries by 2030.

Biosimilars 52

Biosimilars Treatment Government Hospitals 52

Drug Channels

JULY 29, 2022

This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Note that the forecasts below did not account for policy changes that could further reduce pharmaceuticals' share of U.S. healthcare spending.

Pharmacy 84

Pharmacy Drugs Government Pharmaceuticals 84

BioPharma Drive: Drug Pricing

MARCH 1, 2024

Reeling from a difficult year financially, the pharma unveiled a new oncology division it says will produce eight billion-dollar medicines by 2030.

Drug Research 121

Drug Research Research Drugs 121

SCIENMAG: Medicine & Health

NOVEMBER 7, 2023

Brussels, 8 November 2023 – New international research on the economic burden of urinary incontinence reveals that the cost of continence care will reach an estimated €69.1 billion in 2023.

International 80

International Production Research 80

The Pharma Data

NOVEMBER 15, 2020

16, 2020 /PRNewswire/ — Diadem srl , a company developing the first blood-based test for the prediction of early onset Alzheimer’s disease, today announced that it has been selected as a finalist for both the Gaetano Marzotto Company Prize and the Gaetano Marzotto 2030 Social Impact Special Prize. . MILAN , Nov.

Disease 40

Disease Treatment Production Clinical Trials 40

biobide

DECEMBER 1, 2023

Cannabis derivatives In 2022 the global legal cannabis market was valued at USD 22.1 This is forecasted to grow rapidly, with a growth rate of 25.5% A Key contributing factor to this significant growth prediction is the accelerating legalization of cannabis products and the growing acceptance of its use in the medical field and consumer goods.

Treatment 97

Treatment Production Marketing Research 97

Antidote

AUGUST 2, 2022

Not only does it impact many people today, but its prevalence is expected to double by 2030. Mitral valve regurgitation is a common kind of heart disease in the United States.

Disease 98

Disease 98

thought leadership

JUNE 4, 2024

The HTAR will take effect in January 2025 for oncology and/or advanced therapy medicinal product (ATMP) therapies, with other therapies following a staggered implementation process, including orphan drugs in 2028 and all drugs in 2030.

Therapies 59

Therapies Regulations Production Marketing 59

Agency IQ

FEBRUARY 23, 2024

NANCY SKINNER has updated a bill she introduced in early January 2024 to ban the sale of intentionally added PFAS in the state after 2030. BY WALKER LIVINGSTON, ESQ California state Sen. Although the bill may receive state support, the actual implementation of the ban, if passed, would be a herculean task.

59

59

Agency IQ

MAY 10, 2024

BY RAYAN BHARGAVA, MSC | MAY 9, 2024 11:03 PM CDT Regulatory background Until recently, the EU had plans to halve pesticide reduction by 2030. In late October 2023, the French government announced yet another version: Ecophyto 2030. However, intense farmer protests led the French government to pause Ecophyto 2030 indefinitely. [

Government 40

Government Regulations Production Marketing 40

SCIENMAG: Medicine & Health

JUNE 13, 2023

Although there are numerous projects from governments, NGOs, and private corporations who are committed to providing safely managed water and sanitation by 2030, a new study advocates for more holistic evaluation of water, sanitation, and hygiene (WASH) interventions. According to the study by Justin Stoler, associate […]

Government 68

Government 68

biobide

NOVEMBER 20, 2023

projected by the year 2030. Background on the Cosmetics industry In 2022, the value of the global cosmetics market was estimated to be worth USD 262.21 billion, with an annual growth of 4.2%

Packaging 64

Packaging Regulations Production Marketing 64

The Pharma Data

MAY 26, 2023

The report is part of the NCDs Global Action Plan 2023-2030 and is an update from 2017 and is core to the Implementation Roadmap on NCDs. The latest revision was updated to reflect WHO’s recommendations and guidance and the latest scientific evidence on impact.

Disease 52

Disease Government Treatment Production 52

Fierce BioTech

SEPTEMBER 6, 2024

In the coming period, pharma should witness an ongoing transformation, as exclusivity rights to 569 medications valued at $278 billion (2022 sales) are set to expire by 2029/2030.

Marketing 52

Marketing Drugs 52

The Pharma Data

APRIL 12, 2022

per person per year from now until 2030. This investment would realize more than US$ 230 billion in economic and societal benefits and avert nearly 10 million heart attacks and strokes globally by 2030. NCDs are largely preventable and treatable, nearly 7 million lives could be saved for just US$ 0.84

International 52

International Disease Government Treatment 52

The Pharma Data

JUNE 28, 2023

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030 and ensure their long-term survival.

Science 40

Science Government 40

The Pharma Data

MAY 2, 2023

The Network of African Road Safety Legislators Meeting aims to strengthen and align legislation to meet the United Nations global target of halving road crash deaths by 2030. The scourge of road crash deaths is an overlooked, under-reported and preventable public health crisis that hits harder in Africa than anywhere else.

Regulations 40

Regulations Government Drugs 40

The Pharma Data

NOVEMBER 2, 2020

Setting sights on 2030. Despite setbacks due to COVID-19, WHO will accelerate work to achieve this target by 2030. This goal is aligned with the aims of universal health coverage to leave no one behind by 2030. Infections have been brought to such low levels in some areas that 649.1

Packaging 52

Packaging Disease Treatment Drugs 52

The Pharma Data

JUNE 26, 2021

Sanofi Aims for Carbon Neutrality Sanofi has committed to reduce its greenhouse gas emissions by 55% by 2030 in line with limiting global warming to 1.5°C C and is aiming for carbon neutrality by 2050.

Packaging 52

Packaging Vaccine Production Science 52

The Pharma Data

MAY 15, 2023

The Company successfully met its 2030 target to increase energy efficiency, exceeded its 2030 target to reduce total water withdrawal in areas projected to be in water stress and met its 2023 targets to train employees on compliance policies.

Government 40

Government Pharmaceuticals Compliance Production 40

The Pharma Data

NOVEMBER 12, 2020

Committee A, which focuses on programme and budget matters, decided to recommend the adoption of the first-ever resolution on meningitis, which would approve a global roadmap to defeat meningitis by 2030 – a disease that kills 300,000 people annually and leaves one in five of those affected with devastating long-term consequences.

Disease 52

Disease Treatment 52

Drug Target Review

SEPTEMBER 21, 2023

A novel drug, will be needful at this point as it will; help promote WHO’s roadmap for 2021-2030, provide much effective drugs and equal access to healthcare- as people living with onchocercomas will no longer worry about surgical removal of them. Visualise a society free from the inconvenience and pain associated with river blindness.

Drugs 105

Drugs Treatment Disease Research 105

New Drug Approvals

JANUARY 31, 2024

The prevalence of non-alcoholic steatohepatitis (NASH), a form of NAFLD that is associated with hepatic inflammation and ballooning of hepatocytes, is expected to increase by 63% between 2015 and 2030 in the United States (Estes, Hepatology, 2018; 67(1): 123-133), where NASH is expected to become the leading cause of liver transplantation by 2020.

Treatment 52

Treatment Disease Pharmaceuticals Drugs 52

DrugBank

AUGUST 9, 2024

In 2021, an estimated 537 million adults were living with diabetes, a number projected to reach 643 million by 2030. billion by 2030. Similarly, the diabetes market is experiencing substantial growth due to the rising prevalence of this chronic condition. The market for cardiovascular drugs, valued at 155.6

Pharmaceuticals 77

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 77

PPD

OCTOBER 18, 2023

Continued expansion of the biotech industry is occurring in parallel, with an estimated compound annual growth rate of 13.96% from 2023-2030. There has been an unprecedented expansion of different types of pharmaceutical therapies, as well as a change in the overall approach to health care.

Laboratories 52

Laboratories Assay Development Small Molecule Drug Development 52

Perficient: Drug Development

MARCH 14, 2024

billion by 2030. The ability to offer healthcare products and services digitally is more important than ever. In fact, the global healthcare eCommerce market is projected to reach $994.2 But a complex regulatory landscape and data privacy and security concerns are formidable obstacles.

Science 52

Science Pharmacy Marketing Production 52

The Premier Consulting Blog

MAY 4, 2023

billion in 2022 and is expected to grow approximately eight percent from 2023 to 2030 [1]. Ophthalmic drugs market size, share & trends analysis report by drug class, by disease (dry eye, glaucoma), by dosage form, by route of administration, by product type (prescription, OTC), by region, and segment forecasts, 2022-2030.

FDA 52

FDA Packaging Compliance Regulations 52

The Pharma Data

MARCH 11, 2021

Roche is committed to helping countries scale up HIV elimination programs and reach the WHO 2030 goals of 95% of people living with HIV knowing their HIV status; 95% of HIV-positive people on treatment; and 95% of people on treatment having suppressed viral loads. About the cobas Plasma Separation Card.

Disease 52

Disease Treatment Laboratories Virus 52

Drug Target Review

SEPTEMBER 22, 2023

The substantial value of organoids is becoming increasingly recognised by supportive government initiatives developing novel drugs, with a growth rate of 22 percent between 2023 and 2030 and a market size predicted to reach over US $6.5 billion by 2030.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

The Pharma Data

SEPTEMBER 16, 2020

In addition, Novartis further strengthened its carbon neutrality target to aim for full carbon neutrality across its supply chain (Scope 1, 2, 3) by 2030. Novartis recently set new ambitious targets to increase patient reach in low- and middle-income countries by 2025. Our approach to Environmental, Social and Governance topics.

Government 52

Government 52

Perficient: Drug Development

OCTOBER 16, 2024

trillion talent shortage projected by 2030. Addressing the Talent Shortage While fears of AI-driven job displacement dominate headlines, the real crisis looming is a $8.5

Compliance 105

Compliance Production Marketing Research 105

The Pharma Data

DECEMBER 15, 2020

The 2030 Consulting team provides high-caliber tactical contracting and strategic consulting for all aspects of business-to-business software solutions, from software sales and vendor selection to application development, implementation and managed services. Download the whitepaper at: [link].

Science 52

Science Compliance Regulations FDA 52

The Pharma Data

APRIL 7, 2021

In this context, Sanofi, the only pharmaceutical company that keeps developing and supplying treatments for African trypanosomiasis or sleeping sickness, has committed itself alongside the WHO to eliminate this neglected tropical disease in humans by 2030. Zero plastic packaging for vaccines and ecodesign of products.

Vaccine 52

Vaccine Packaging Disease Treatment 52

The Pharma Data

NOVEMBER 5, 2020

Since May, Member States have adopted a number of decisions – the Immunization Agenda 2030, the Decade of Healthy Ageing 2020-2030, as well as initiatives to tackle cervical cancer, tuberculosis, eye care, food safety, intellectual property and influenza preparedness.

International 52

International Compliance Virus Vaccine 52

Vial

MAY 20, 2024

billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030. In this article, we will define preclinical and clinical CROs, as well as highlight the unique needs and challenges of these organizations in their respective stages of drug research. What is a Pre-Clinical CRO? over this period.

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

LifeSciVC

APRIL 26, 2024

Fourth, the venture exit environment circa 2027-2030 for the new crop of early stage startups being created today will likely have structural supply/demand elements more favorable than the backdrop in recent years. Fewer startups over time should ameliorate this crowding dynamic to some extent.

DNA 110

DNA Science Marketing Clinical Trials 110